PF-Atlas › Clinical Trials › NCT03525444
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation
VX-445/TEZ/IVA · Phase 3
Registry ID
NCT03525444
Phase
Phase 3
Status
Completed
Drug / intervention
VX-445/TEZ/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2018-06-15
About this trial
VX-445/TEZ/IVA is evaluated in NCT03525444, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT03525444 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.